Shareholders Approve New Omnibus Incentive Plan, Re-elect Directors
GNTX sits 18% above its 52-week low of $20.48 on light trading volume (0.1× avg).
Summary
Gentex shareholders approved a new equity incentive plan and re-elected directors at their annual meeting, formalizing future share-based compensation and routine governance matters.
Key Events · Corporate Governance and Compliance · GNTX
-
2026 Omnibus Incentive Plan Approved
Shareholders approved the Gentex Corporation 2026 Omnibus Incentive Plan, authorizing future equity awards for employees and directors. This formalizes a proposal from the April 9, 2026 proxy statement.
-
Directors Re-elected
All nine nominated individuals were re-elected to serve as directors for a one-year term expiring in 2027.
-
Auditor Ratified
Shareholders ratified the appointment of Ernst & Young LLP as the company's independent auditors for the fiscal year ending December 31, 2026.
-
Executive Compensation Approved (Advisory)
Shareholders approved, on an advisory basis, the compensation of the company's named executive officers.
Analysis · GNTX · Manufacturing
Gentex shareholders approved the 2026 Omnibus Incentive Plan at their annual meeting, formalizing the authorization for future equity awards to employees and directors. This finalizes a proposal initially detailed in the April 9, 2026 proxy statement. While a standard corporate action, it enables future dilution. Shareholders also re-elected all nominated directors and ratified the company's auditors.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 29.5% of the 2875 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GNTX was trading at $24.09 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $20.48 to $29.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.